Insider Daniel Thomas O. Buys 10,000 Gossamer Bio Options Amid New‑Drug NDA—Signals Confidence in FDA‑Driven Upside

Insider Buying Signals a Strong Commitment to the New‑Drug Push On September 23, 2026, board member Daniel Thomas O. exercised a stock‑option grant for 10,000 shares of Gossamer Bio at $0.00, adding those shares to his post‑transaction holding. The move comes just days after the company filed its first NDA for seralutinib, its Phase 3 lead product for pulmonary arterial hypertension. While the option’s exercise price is zero—typical for internal grants—Thomas’s action reflects confidence that the company’s valuation will rise once FDA acceptance and eventual market launch materialize. Investors already noted a 1.96 % weekly gain in the stock, and the social‑media sentiment score of +9 paired with a 698 % buzz spike indicates that the insider’s activity is resonating with the community.

What the Transaction Means for Shareholders Gossamer’s market cap sits at $67.2 million, and its price‑earnings ratio is a negative –0.24, underscoring that the company is still pre‑profit and heavily reliant on future product revenue. Thomas’s purchase signals that insiders believe the upcoming regulatory milestones will unlock shareholder value, potentially reversing the 21.41 % monthly decline and the 95.15 % yearly drop that have weighed on the stock. If the FDA’s pre‑NDA meeting is followed by a favorable filing, the company’s share price could experience a significant upside, especially given the 52‑week high of $309.60 and the current low of $9.12.

A Profile of Daniel Thomas O. Thomas has a history of buying sizable option blocks—115,000 shares in June 2026 and now 10,000 shares in September—showing a pattern of accumulating equity rather than liquidating. His purchases coincide with key corporate events: the June buy occurred shortly after the company’s first quarter earnings and a strategic partnership announcement, while the September buy follows the NDA filing. Unlike some insiders who trade in common stock, Thomas sticks to options, suggesting he is leveraging vesting schedules to align his interests with long‑term company performance. This disciplined approach has earned him a reputation among peers for “patient‑capital” investing in early‑stage biotechs.

Investor Takeaway For investors, Thomas’s recent buy adds a layer of credibility to Gossamer’s ambitious clinical pipeline. The insider’s action, coupled with the spike in social‑media buzz, should prompt a closer look at the company’s regulatory timeline and commercial strategy. While the stock remains volatile—evidenced by a sharp annual decline and negative earnings—a strategic insider buy coupled with the NDA filing could herald a turning point. Those willing to endure short‑term price swings may find the 2026–2027 period a potentially rewarding window, provided the FDA’s review proceeds without major setbacks.